Cargando…

The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations

BACKGROUND: The U.S. Food and Drug Administration (FDA) is the regulatory agency responsible for approving all pharmaceutical products marketed in the United States. While the FDA does not conduct research for developing pharmaceutical products, the agency does review all of the scientific evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchand, Heidi C., Rose, Brenda J., Fine, Anna M., Kremzner, Mary E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437529/
https://www.ncbi.nlm.nih.gov/pubmed/23206214
http://dx.doi.org/10.18553/jmcp.2012.18.9.713
_version_ 1785092546216591360
author Marchand, Heidi C.
Rose, Brenda J.
Fine, Anna M.
Kremzner, Mary E.
author_facet Marchand, Heidi C.
Rose, Brenda J.
Fine, Anna M.
Kremzner, Mary E.
author_sort Marchand, Heidi C.
collection PubMed
description BACKGROUND: The U.S. Food and Drug Administration (FDA) is the regulatory agency responsible for approving all pharmaceutical products marketed in the United States. While the FDA does not conduct research for developing pharmaceutical products, the agency does review all of the scientific evidence that a pharmaceutical sponsor submits and ensures that it demonstrates U.S. regulatory standards for the product and meets approval requirements. OBJECTIVES: To provide insights, for the managed care pharmacist, into the agency’s decision-making process and into the recommendations for appropriate usage and regulatory recommendations for risk mitigation by pharmaceutical sponsors. METHODS: The FDA website contains a vast amount of clinically useful and meaningful information. This review focused on specific topics within the website that can be useful for the managed care pharmacist, including the following: (a) the FDA’s review and evaluation of new drug applications (NDA), supplemental new drug applications (s-NDA), and biological new drug applications (BLA); (b) materials regarding a therapeutic product presented to a public FDA advisory committee meeting; and (c) the postmarket requirements and commitments database that provides information on the studies that a sponsor must conduct to maintain a product’s approval for marketing in the United States. RESULTS: This review examined the drug information contained on the FDA’s website and summarized the FDA’s medical and technical review, analysis and decision processes. Detailed drug information provided to the FDA by the pharmaceutical sponsor demonstrating a product’s efficacy and safety is publically available upon the product’s approval. CONCLUSIONS: For the managed care pharmacist involved with formulary review and recommendations, the FDA’s website contains information that is available to provide insight into the agency’s evaluation process and decision making for marketed pharmaceutical products. Use of these materials and understanding the regulatory context under which medical products are reviewed and approved may assist managed care pharmacists in making informed recommendations for use of the products within the context of their health systems.
format Online
Article
Text
id pubmed-10437529
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-104375292023-08-21 The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations Marchand, Heidi C. Rose, Brenda J. Fine, Anna M. Kremzner, Mary E. J Manag Care Pharm Formulary Management BACKGROUND: The U.S. Food and Drug Administration (FDA) is the regulatory agency responsible for approving all pharmaceutical products marketed in the United States. While the FDA does not conduct research for developing pharmaceutical products, the agency does review all of the scientific evidence that a pharmaceutical sponsor submits and ensures that it demonstrates U.S. regulatory standards for the product and meets approval requirements. OBJECTIVES: To provide insights, for the managed care pharmacist, into the agency’s decision-making process and into the recommendations for appropriate usage and regulatory recommendations for risk mitigation by pharmaceutical sponsors. METHODS: The FDA website contains a vast amount of clinically useful and meaningful information. This review focused on specific topics within the website that can be useful for the managed care pharmacist, including the following: (a) the FDA’s review and evaluation of new drug applications (NDA), supplemental new drug applications (s-NDA), and biological new drug applications (BLA); (b) materials regarding a therapeutic product presented to a public FDA advisory committee meeting; and (c) the postmarket requirements and commitments database that provides information on the studies that a sponsor must conduct to maintain a product’s approval for marketing in the United States. RESULTS: This review examined the drug information contained on the FDA’s website and summarized the FDA’s medical and technical review, analysis and decision processes. Detailed drug information provided to the FDA by the pharmaceutical sponsor demonstrating a product’s efficacy and safety is publically available upon the product’s approval. CONCLUSIONS: For the managed care pharmacist involved with formulary review and recommendations, the FDA’s website contains information that is available to provide insight into the agency’s evaluation process and decision making for marketed pharmaceutical products. Use of these materials and understanding the regulatory context under which medical products are reviewed and approved may assist managed care pharmacists in making informed recommendations for use of the products within the context of their health systems. Academy of Managed Care Pharmacy 2012-11 /pmc/articles/PMC10437529/ /pubmed/23206214 http://dx.doi.org/10.18553/jmcp.2012.18.9.713 Text en Copyright © 2012, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Formulary Management
Marchand, Heidi C.
Rose, Brenda J.
Fine, Anna M.
Kremzner, Mary E.
The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
title The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
title_full The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
title_fullStr The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
title_full_unstemmed The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
title_short The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
title_sort u.s. food and drug administration: drug information resource for formulary recommendations
topic Formulary Management
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437529/
https://www.ncbi.nlm.nih.gov/pubmed/23206214
http://dx.doi.org/10.18553/jmcp.2012.18.9.713
work_keys_str_mv AT marchandheidic theusfoodanddrugadministrationdruginformationresourceforformularyrecommendations
AT rosebrendaj theusfoodanddrugadministrationdruginformationresourceforformularyrecommendations
AT fineannam theusfoodanddrugadministrationdruginformationresourceforformularyrecommendations
AT kremznermarye theusfoodanddrugadministrationdruginformationresourceforformularyrecommendations
AT marchandheidic usfoodanddrugadministrationdruginformationresourceforformularyrecommendations
AT rosebrendaj usfoodanddrugadministrationdruginformationresourceforformularyrecommendations
AT fineannam usfoodanddrugadministrationdruginformationresourceforformularyrecommendations
AT kremznermarye usfoodanddrugadministrationdruginformationresourceforformularyrecommendations